Introduction
Schwann cells transplanted into the CNS can promote the regeneration of CNS axons and replace lost myelin (Takami et al., 2002; Pearse et al., 2007) . They can be expanded in vitro from nerve explants or skin-derived stem cells and are therefore potentially useful as autografts for spinal cord repair and peripheral nerve bridges (Morrissey et al., 1991; Casella et al., 1996; Guest et al., 1997; Bunge and Pearse, 2003; Biernaskie et al., 2007; Bunge, 2008) . Although many studies have demonstrated the potential of Schwann cells for these applications, some problems have to be addressed to make them useful (Dam-Hieu et al., 2002; Takami et al., 2002; Biernaskie et al., 2007; Pearse et al., 2007; Tabesh et al., 2009) .
One of the main problems is that the cells show very limited migration from the site of implantation and do not intermingle with host astrocytes (Sims and Gilmore, 1994; Sims et al., 1998; Fraher, 1999; Lakatos et al., 2000; Andrews and Stelzner, 2007) . Interfaces between Schwann cell and astrocyte territory are characterized by a sharp boundary of reactive astrocytes expressing, among other molecules, inhibitory chondroitin sulfate proteoglycans (CSPGs) (Geller and Fawcett, 2002; Silver and Miller, 2004) . Although many axons cross this inhibitory boundary to enter the Schwann cell grafts, few axons leave the attractive Schwann cell environment back into the CNS territory to make connections with host neurons (Richardson et al., 1982; Adcock et al., 2004; Li et al., 2005) . Similarly, coculture of Schwann cells and astrocytes shows separate territories with sharp boundaries between them (Ghirnikar and Eng, 1995; Wilby et al., 1999; Lakatos et al., 2000) . Addition of neurons on these cultures shows that their axons grow preferentially on the Schwann cells and seldom leave the Schwann cell environment to grow on astrocytes (Adcock et al., 2004) .
The molecular interactions involved in the segregation of Schwann cells and astrocytes and in the inhibition of Schwann cell migration in astrocyte territories are only partially understood. One candidate is Eph/ephrin-mediated cell repulsion. Eph/ephrin interactions lead to the segregation and sorting of various cell types, formation of rhombomere boundaries, guidance of neural crest migration, and repulsion of growth cones (Krull et al., 1997; Monschau et al., 1997; Robinson et al., 1997; Smith et al., 1997; Gao et al., 1998; Mellitzer et al., 1999; Kullander et al., 2001; Xu et al., 1995 Xu et al., , 2000 . EphrinB2 on reactive astrocytes and EphB2 on fibroblastic meningeal cells are involved in the formation of the astrocyte-meningeal boundary (Bundesen et al., 2003) . An important route of Eph signaling is via the VAV guanidine nucleotide exchange factor (GEF) family, which modulates the activity of Rho, Rac, and Cdc42 (Hornstein et al., 2004) .
In this study, we investigate the expression profile of Ephs and ephrins on Schwann cells. We demonstrate that Schwann cell migration is inhibited by ephrinAs and that blocking astrocyte-produced ephrinAs allows Schwann cell-astrocyte mixing. We further show that ephrin signaling involves the VAV pathway and influences integrin-mediated Schwann cell migration.
Materials and Methods
Antibodies and reagents. Antibodies used were as follows: mouse monoclonal anti-rat p75 (1:1000; Millipore Bioscience Research Reagents), rabbit polyclonal anti-GFAP (1:500; Dako), chicken polyclonal anti-GFAP (1:2000; Abcam), rabbit polyclonal phospho-VAV2 (pVAV2) tyr172 (1:1000; ECM Biosciences), rabbit monoclonal anti-VAV2 (1: 1000; Abcam), rabbit polyclonal anti-phospho-focal adhesion kinase (FAK) tyr397 (1:100; Invitrogen), rabbit polyclonal anti-S100 (1:500; Dako), rabbit anti-EphA4 (1:1000; generous gift from Dr. Wilkinson, Medical Research Council, London, UK), mouse monoclonal antiEphA2 (1:1000; Millipore Corporation), hamster anti-rat ␤1 blocking antibody (1:200; BD Pharmingen), hamster anti-␤3 blocking antibody (1:200; BD Pharmingen), rabbit polyclonal anti-FAK (1:100; Biosources), anti-mouse/rat CD29 -FITC-conjugated antibody (1:200; Biolegends), mouse polyclonal anti-ephrinA5 (1:1000; Abcam), rabbit polyclonal anti-ephrinA5 (1:1000; Abcam), and mouse monoclonal antiEphA7 (1:500; Abcam). Alexa fluor-conjugated secondary antibodies were all obtained from Invitrogen and used at 1:500 dilutions. Ephrins and Eph-Fc were purchased from R & D Systems (used at 10 g/ml). Goat anti-human secondary antibody (Jackson ImmunoResearch) was used for clustering ephrin-Fc in 1:10 ratio.
MnCl 2 ⅐4H 2 O (Sigma) was used at 500 M, and laminin (Sigma) was used at 1 g/ml.
DMEM, HBSS, and fetal calf serum (FCS) were all purchased from Invitrogen. Penicillin-streptomycin-fungizone (Sigma) was used at 1%.
Schwann cell cultures. Schwann cells were prepared from postnatal day 1-3 Sprague Dawley rat sciatic nerves, using a variation of a procedure described previously (Brockes et al., 1979) . Sciatic nerves were cleared of their epineurium and then incubated in collagenase (0.03%; Sigma) for 15 min, followed by trypsin (0.1%; Sigma) for 15 min. Triturating solution [containing 300 mg of BSA (Sigma), 1 mg of DNase (Sigma), and 50 mg of trypsin inhibitor (Sigma) per 100 ml HBSS] was added, and the nerves were triturated. Centrifuged cells were resuspended in DMEM/ 10% FCS on laminin (1 g/ml; Sigma) or poly-D-lysine (PDL) (20 g/ml; Sigma) coated flasks. From day 2, cytosine arabinoside (1 ϫ 10 Ϫ5 M; Sigma) was added for 2 d, followed by 2 d in DMEM/10% FCS, repeated twice. Remaining fibroblasts were removed using complement lysis with anti-Thy1.1 antibody (1:5 hybridoma cell supernatant T11D7) and rabbit complement (1:5; Serotec). Schwann cells were then proliferated in DMEM, 10% FCS, 2 M forskolin (Calbiochem), and bovine pituitary extract (BPE) (10 g/ml; Sigma).
Astrocyte cultures. Astrocyte culture technique was adapted from McCarthy and de Vellis (1980) .
Cortices of neonatal day 1-3 Sprague Dawley rat pups were demembranated, chopped, incubated with 0.1% trypsin for 30 min, triturated in triturating solution, resuspended in DMEM/10% FCS, and plated in PDL-coated 75 cc flasks. After 7-10 d, microglia and oligodendrocyte precursor cells were removed from the astrocytes by shaking for 15 h at 50 rpm at 37°C (Luckham R300).
Migration assay. The inverted coverslip assay is a variation of that first described previously (Fok-Seang et al., 1995; Wilby et al., 1999) . Coverslip fragments were coated with PDL, and then an equal number of Schwann cells in 20 l drops were placed on each coverslip fragment. After 2 h, medium was added to cover the fragments. The cells were incubated in Schwann cell medium containing BPE (10 g/ml; Sigma) and forskolin (2 M; Calbiochem) for 24 h. The coverslip fragments were inverted face down on to the test surface after repeated dipping to remove poorly attached cells. Cells were allowed to migrate for 24 -48 h, fixed in 4% paraformaldehyde, and stained for p75. The maximum distance of migration and the number of cells migrating at each distance was measured. Each data point is the mean of at least three coverslips, repeated at least three times using independent cell batches.
In experiments involving ephrins, soluble ephrins-Fc (R & D Systems) were preclustered with goat anti-human secondary antibody (Jackson ImmunoResearch) at 1:10 for 1 h at room temperature. The preclustered ephrins were applied to cultures at 10 g/ml.
Boundary assay. A 50 l droplet of Schwann cell suspension (2 ϫ 10 6 cells/ml) was placed at one end of a PDL-coated chamber slide well (Nalge Nunc International), and a glass strip was used to smear the drop toward the center of the chamber to generate a straight edge. A second 50 l drop containing astrocytes was placed at the opposite end of the well and smeared to give a straight edge parallel to and 0.2 mm from the first. After 2 h, cultures were washed to remove non-attached cells and then grown for 10 d in DMEM supplemented with BPE/forskolin. In experiments involving EphA4 -Fc, the medium was changed to DMEM supplemented with 10% FCS before the start of the experiment. EphA4 (10 g/ml; R & D Systems) was added to the medium every 24 h for 3 d. For quantification. a line was drawn at the front edge of astrocyte territory, and then the number of Schwann cells migrating into astrocyte territory was counted at distances of 100, 200, and Ͼ200 m. Experiments were repeated at least three times with independent cell batches.
Immunocytochemistry. Cells were fixed for 15 min in 4% paraformaldehyde, washed, and blocked in 0.2% Triton-X and 10% goat serum for 40 min. Primary antibody (see above) with 10% goat serum was incubated overnight. The cells were then washed and incubated with secondary antibody for 1 h. The excess secondary antibody was then removed by three washes. The coverslips were then mounted onto slides using fluorosave. For experiments looking at the surface level of integrins, no Triton-X was used. For DAB staining, biotinylated secondary antibodies were used: anti-mouse (1:200; Vector Laboratories) or anti-rabbit (1: 200; Vector Laboratories) for 1 h. This was followed by washes and subsequent addition of streptavidin ABC Elite kit (Vector Laboratories) for 1 h and then DAB (Sigma). For live staining, primary antibodies were added to the medium for 15 min, followed by three washes using PBS. The secondary antibodies were then incubated with cells for an additional 15 min. The cells were then washed and fixed using ice-cold methanol for 3 min.
Reverse transcriptase-PCR. RNA was extracted from purified primary sciatic nerve Schwann cells and primary cortical astrocytes derived from postnatal days 1-3 Sprague Dawley rats. For positive controls for Eph and ephrin screening, RNA was extracted from embryonic day 13 hindbrain from rat.
Total RNA was isolated with TRIzol (Invitrogen). RNA was subjected to reverse transcription (RT) with Superscript II First-Strand Synthesis System (Invitrogen).
cDNA was amplified by an initial incubation at 94°C for 7 min, followed by 35 cycles of 35 s denaturation at 94°C, 30 s primer annealing at 59°C, and 40 s for primer extension at 72°C. Final extension was performed at 72°C for 5 min. The PCR products were electrophoresed and analyzed with a 1.5% agarose gel.
Primer sequences for VAV2 are shown in supplemental RNA interference experiments. VAV2 small interfering RNA (siRNA) was purchased from Dharmacon (On Target Pool): CAGCAGAGGCA-GAGCGUUU; GGUGGAAGGGCGAGACGAA; GUGAAGAUCUA-CAGCCGGA; and GGAUGGAGCAGUUCGAGAU. VAV2 siRNA used in supplementary experiments was from Invitrogen: CCACAUCACG-GAAGCUAAGAAGUUU; AAACUUCUUAGCUUCCGUGAUGUGG). Control siRNA was purchased from Invitrogen. Lipofectamine 2000 (Invitrogen) was used as the transfection reagent.
Assessment of knockdown was achieved by RT-PCR and immunostaining. RNA was isolated from pelleted cells using acid guanidinium phenol chloroform, treated with DNase, and then reverse transcribed. PCR was performed as above, using the VAV2 primers. Three different cycle numbers were used so as to achieve a semiquantitative result.
Schwann cells in 1-cm-diameter laminin-coated wells were treated for 5 h with VAV2 siRNA using Lipofectamine 2000 as the transfection reagent. Twenty-four hours later, Schwann cells were replated on coverslip fragments coated with PDL. After 24 h, the coverslip fragments were inverted onto astrocytic monolayers for migration assays for an additional 24 h.
Western immunoblotting. Briefly, culture medium was taken off from the cultured cells. The cells were washed with ice-cold PBS before being scrapped from the substratum with cold lysis buffer (50 mM HEPES, 150 mM NaCl, 10% glycerol, 1.5 mM MgCl 2 , 1 mM EDTA, and protease inhibitor cocktail). The suspension was collected and passed through a 30 gauge needle three times. The lysate was briefly centrifuged with 1000 ϫ g for 5 min to remove cell debris. The supernatant was then ultracentrifuged at 100,000 ϫ g for 1 h at 4°C. The supernatant, which contains soluble proteins, was transferred to a clean Eppendorf. The pellets were dissolved in lysis buffer again with 1% Triton X-100. Protein concentration was determined using BCA Protein Assay kit (reducing agent compatible; Pierce).
Twenty micrograms of proteins were electrophoresed in a 4 -20% Tris-Bis polyacrylamide gel (Invitrogen) at 120 V for 70 min. After separation by electrophoresis, proteins were transferred to polyvinylidene difluoride membrane (GE Healthcare) at 4°C for 3 h at 35 V. Membranes were washed twice in TBS containing 0.05% Tween 20 (TBS/T) and blocked with 5% skimmed milk (Marvel) in TBS/T. It was then incubated with primary antibodies in TBS/T (with 5% skimmed milk) overnight at 4°C. Primary antibodies used were as follows: monoclonal anti-ephrinA5 antibody (1:1000; Abcam) and rabbit polyclonal anti-EphA4 antibody (1:2500; generous gift from Dr. Wilkinson). Membranes were washed five times in TBS/T and incubated for 1.5 h in TBS/T containing peroxidase-conjugated secondary antibodies (1:75,000; Vector Laboratories). Membranes were washed five times in TBS/T, and proteins were visualized using a chemiluminescent substrate (ECL Plus; GE Healthcare). After visualization with the first set of antibodies, the membrane was stripped with 0.1 M glycine, pH 2.5, with 0.05% Tween 20 at 37°C for 30 min. The membrane was washed thoroughly with an ample amount of TBS/T before probing with the second set of antibodies.
Quantification of immunostaining. NIH Image J software was used to measure the integrated pixel density of staining for Schwann cells in each group. For each cell, signal intensity of pFAK or pVAV2 was calculated and background intensity was subtracted. Signal intensity for each cell was then standardized to the corresponding internal p75 immunostaining levels to take account of variation in cell size and morphology. An average of the signal intensity ratio of pFAK/p75 or pVAV2/p75 were then calculated for each group. The values were then normalized to the value obtained for the control group. The experiments were repeated at least three times, and total average was calculated.
For quantification of Schwann cells in boundary assays, Schwann cells were identified with p75 staining and astrocytes with GFAP. Schwann cells in direct contact with hypertrophied astrocytes were identified with Schwann cells in the same field that contacted only other Schwann cells as control cells. For each intensity measurement for Schwann cells in contact, a noncontacting control cell measurement from the same field was identified. The signal intensity was standardized to the corresponding p75 levels for each cell to take account of variation in cell size and morphology. Signal intensity for pFAK/pVAV was given as a ratio to the p75 staining level for each cell. pFAK/pVAV2 readings in Schwann cells contacting astrocytes were then normalized to noncontacting control cell values. The experiments were repeated three times, and a total average was calculated.
Statistical analysis. For Student's t test, in Schwann cell migration assays involving two groups, the number of cells migrating from the edge of coverslip was compared with that of the control at the same distance. For comparisons involving more than two groups, one-way ANOVA test was performed, followed by the Bonferroni's post hoc test to compare the different pairs with each other. Throughout, *p Ͻ 0.05, **p Ͻ 0.01, and ***p Ͻ 0.001.
Results

Eph/ephrin expression in Schwann cells and astrocytes
The profile of Eph and ephrins expressed by Schwann cells has not been previously documented. We characterized the ephrinA profile in purified astrocytic cultures (postnatal days 1-3) and demonstrated that all ephrinA mRNAs are present in astrocytes (Table 1) . The RT-PCR findings are in agreement with other studies that have previously shown the presence of ephrinAs in the astrocytes (Winslow et al., 1995; Sobel, 2005) . We further characterized the ephrin and Eph profile in purified Schwann cells (postnatal days 1-3) showing that Schwann cells have complementary sets of receptors on their surface that may interact with ephrinAs on astrocytes ( Table 2) .
EphrinAs inhibit Schwann cell migration
Following the hypothesis that astrocyte-produced ephrins might inhibit Schwann cell migration, we assayed the effect of clustered ephrins in solution on Schwann cell migration on laminin (1 g/ml) using the inverted coverslip assay (Fok-Seang et al., 1995; Wilby et al., 1999) . We tested the effect of clustered ephrinAs and ephrinBs, using 16 h migration assays in the presence of 10 g/ml ephrin. Of the ephrins that were tested, ephrinA1, ephrinA3, and ephrinA5 reduced migration, with ephrinA5 having the greatest effect (Fig. 1A-C) . We confirmed using immunocytochemistry that ephrinA5 is abundantly present on astrocyte cultures (Fig. 1 D) . In all subsequent experiments in this study, therefore, clustered ephrinA5 was used to examine the mechanism of ephrin action. Other ephrins tested, including ephrinB1, ephrinB2, and ephrinB3, did not affect Schwann cell migration.
EphAs in Schwann cells mediate the inhibitory effect of astrocyte ephrinAs
From the Schwann cell Eph screen reported above, the possible receptors for ephrinA5 are EphA4, EphA2, and EphA7. We confirmed the presence of EphA4 and EphA2 in purified Schwann cell cultures using immunocytochemistry (Fig. 2 A, B) . To investigate whether astrocyte-produced ephrinAs act on Schwann cell receptors such as EphA4 to inhibit their migration, we performed assays in the presence of soluble EphA4 -Fc, which has been shown in previous studies to act as a blocker of the action of ephrinAs (Goldshmit et al., 2004) . We first examined Schwann cell migration over confluent astrocyte monolayers using 48 h inverted coverslip migration assays, with the EphA4 -Fc refreshed after 24 h. As in previous experiments, Schwann cell mi- 
gration on astrocytes was very limited. The presence of EphA4 -Fc (10 g/ml) increased the number of Schwann cells migrating on astrocytic monolayers (Fig. 2C) . We further assessed the effect of soluble EphA2-Fc on Schwann cell migration on astrocytes because EphA2 mRNA was also detected in the screen for possible receptors; however, no effect was seen using this peptide on the migratory behavior of cells in the assay (Fig.  2 D) . Similarly, the presence of EphA7 was also confirmed using immunostaining. However, the addition of EphA7-Fc had no effect on Schwann cell migration on astrocytes (supplemental Fig. 2 , available at www.jneurosci.org as supplemental material). Quantification of immunostaining of EphA receptors showed higher levels of EphA4 receptor on Schwann cells compared with EphA2 and EphA7 (supplemental Fig. 3 , available at www. jneurosci.org as supplemental material).
Next we performed a Schwann cell-astrocyte confrontation assay, which more closely models the interface formed between the two cell types after transplantation (Wilby et al., 1999; Lakatos et al., 2000) . In this assay, dense suspensions of Schwann cells and astrocytes are plated onto PDL-coated coverslips using a straight-edged coverslip. This produces confluent Schwann cell and astrocyte monolayers with straight edges and a Ͻ0.5 mm gap between them. The monolayers grow together in a few days, and, because the cell types are resistant to mixing, a clear straight Schwann cell-astrocyte interface results with occasional Schwann cells trapped among the astrocytes (Fig. 3A) . We applied EphA4 -Fc peptide for 48 h during the time when the monolayers came together (Fig. 3B ). This produced a marked increase in the number of Schwann cells that had penetrated within astrocytic territory, mostly within the 100 m from the edge of the astrocytic boundary (Fig. 3C) .
In addition to blocking the interaction of ephrinAs with EphA receptors, EphA4 -Fc in solution can cause reverse signaling with the ephrin as receptor. We therefore further assessed the effect of soluble EphA4 -Fc (10 g/ml) on Schwann cell migration on laminin (1 g/ml) over 24 h using the inverted coverslip assay. Application of this peptide had no effect on the Schwann cell migration, demonstrating that the effect of EphA4 peptide on Schwann cell migration on astrocytic monolayers and in boundary assays is not attributable to reverse signaling via ephrins on Schwann cells (Fig. 3D) . We cannot exclude an additional effect of EphA4 peptide on astrocytes, and previous experiments have shown that EphA4 receptor is involved in astrocytosis and EphA4 knock-out mice show reduced glial scar formation (Goldshmit et al., 2004) . Our data suggest that astrocyte-produced ephrinAs (particularly ephrinA5) act on Schwann cell EphAs to mediate the inhibitory effect of astrocytes on Schwann cell migration and intermixing of the two cell types.
Because both Schwann cells and astrocytes express ephrinA5 and EphA4, it is necessary to see different levels of expression of these molecules on Schwann cells and astrocytes if they are to play a part in establishing a boundary between the two cell types. Western immunoblotting for proteins in membrane fraction demonstrated that astrocytes express higher levels of ephrinA5, with Schwann cells expressing higher levels of EphA4 (Fig. 3E) . Coomassie Brilliant Blue confirmed the equal amount of protein loading. This further supports a role of differential expression of EphrinA5-induced repulsion in establishing the boundary between the astrocytes and Schwann cells.
Signaling from EphA receptor in Schwann cells
We investigated the possibility that VAV proteins are the signaling pathways downstream from EphA4 in Schwann cells. VAV2 has been shown previously to be recruited and phosphorylated after activation of EphA receptors (Cowan et al., 2005) . The main VAV present in Schwann cells has been shown to be VAV2 (Yamauchi et al., 2004) . We first confirmed this previous finding by demonstrating the presence of VAV2 in our Schwann cells by immunostaining (Fig. 4 A, B,F ) . Activation of VAV2 can be detected using antibodies that recognize the phosphorylated form of the molecule. We therefore assessed the effect of the addition of soluble clustered ephrinA5 on VAV2 phosphorylation in Schwann cells cultured on laminin. Addition of clustered ephrinA5 led to an increase in VAV2 phosphorylation at the 10 min time point (Fig. 4 A, B) . Quantification of the immunostaining revealed a 43.7% increase in pVAV2 levels after treatment with the clustered ephrinA5 (n ϭ 3; t test, *p Ͻ 0.05).
If astrocyte-produced ephrinAs are responsible for inhibiting Schwann cell migration, it should be possible to see increased phosphorylation of VAV2 in Schwann cells that are in contact with astrocytes. We therefore examined the phosphorylation status of VAV2 in cultures in which we had set up boundaries between Schwann cells and astrocytes. We found that Schwann cells directly in contact with hypertrophied astrocytes show higher levels of pVAV2 compared with cells not in contact with astrocytes within the same field (Fig. 4 D-F ) . Quantification of immunostaining for pVAV2 showed a 38.5% increase in Schwann cells in contact with hypertrophied astrocytes compared with that of control (n ϭ 3; t test, **p Ͻ 0.01). Levels of pVAV2 in each cell was normalized to the p75 immunostaining to ensure that the increase in pVAV2 immunoreactivity was not attributable to artifactual changes in Schwann cell morphology.
These results suggest that astrocyteproduced ephrinAs cause Eph-mediated phosphorylation of VAV2 in Schwann cells where the cell types come into contact. We therefore investigated whether reduction of levels of VAV2 using siRNA treatment of Schwann cells would affect Schwann cell-astrocyte interactions. Knockdown of VAV2 was assessed using RT-PCR and immunostaining of the cells (Fig. 5A-C) . Both techniques demonstrated efficient knockdown of VAV2 at 48 h after application of the siRNA, but no change was observed using control siRNA or in the levels of the housekeeping gene hypoxanthine-guanine phosphoribosyltransferase. Assessment of VAV2 knockdown at 48 h by immunostaining shows protein levels of ϳ50% of control at the time of start of the migration assays (n ϭ 3; t test, *p Ͻ 0.05).
At 48 h after applying the siRNA to Schwann cells, their migration on astrocytic monolayers was assessed using the inverted coverslip assay. VAV2 siRNA-treated Schwann cells showed a marked increase in cell migration on the surface of astrocytes compared with that of control siRNA-treated cells (Fig. 5D-F ) . This finding further strengthens the evidence that 
Ephrins affect Schwann cell integrins
Integrins play a major role in Schwann cell migration (Milner et al., 1997) . In the experiments above, we have studied Schwann cell migration on laminin, which has been shown previously to be a ␤1 integrin-dependent phenomenon (Milner et al., 1997) .
We have shown that Schwann cell migration on astrocytes is also largely dependent on the ␤1 class of integrins but not ␤3 integrins (supplemental Fig. 1 , available at www.jneurosci.org as supplemental material). Eph and ephrins have been shown previously to influence integrins, and a direct effect of EphA activation on the phosphorylation of FAK and on integrin function has been shown previously in epithelial cells and neurons (Miao et al., 2000; Bourgin et al., 2007) . It is therefore likely that EphA activation inhibits Schwann cell migration through modulation of integrin function. We therefore investigated the effect of ephrinA5-induced activation of Eph receptors on the modulation of Schwann cell integrins. Integrin downstream signaling passes via FAK, and phosphorylation of FAK occurs when activated integrins link to their ligand. Phosphorylation of FAK at tyrosine residue 397 has been shown previously to be associated with integrin activation (Sawai et al., 2005) , and Eph receptors have been shown to be able to reduce phosphorylation of FAK (Miao et al., 2000; Bourgin et al., 2007) . To assess the effect of ephrinA5 on Schwann cell integrin signaling, the influence of ephrinA5 on the phosphorylation of FAK was determined. Addition of soluble clustered ephrinA5 to Schwann cells cultured on laminin (1 g/ml) led to 31.3% reduction in the phosphorylation of FAK within 10 min (Fig. 6 A, B) (n ϭ 3; t test, *p Ͻ 0.05), demonstrating that Eph activation in Schwann cells affects integrin signaling.
From the preceding result, if the inhibition of migration of Schwann cell migration by astrocytes is mediated by ephrins, FAK phosphorylation should be reduced where the two cell types are in contact. We therefore set up confrontation cultures in which a Schwann cell-astrocyte boundaries form, where pFAK levels in Schwann cells at the boundary edge are measured after immunostaining. We find that Schwann cells directly in contact with astrocytes show reduced pFAK levels compared with Schwann cells in the same cultures and the same field of view that are not in contact with astrocytes (Fig. 6C,D) . Quantification of pFAK levels in Schwann cells in contact with astrocytes showed a 36.6% reduction in the levels of pFAK compared with that of noncontacting Schwann cells (n ϭ 3; t test, **p Ͻ 0.01). Levels of pFAK for each cell were normalized to p75 immunostaining to ensure that the decrease in pFAK immunoreactivity was not attributable to artifactual changes in Schwann cell morphology. This finding suggests that astrocyteproduced ephrin affects Schwann cell integrin signaling. Integrin activating agents such as Mn 2ϩ have been shown previously to increase the affinity of the integrins to their ligands (Mould et al., 1995) and to reverse the inhibitory effect of molecules intercepting integrin function (Miao et al., 2000; Hu and Strittmatter, 2008) . We therefore asked whether activation of integrins with Mn 2ϩ would reverse the inhibitory effect of ephrinA5 on Schwann cell migration on laminin. Soluble clustered EphrinA5 was applied to Schwann cells in the presence or absence of 500 M Mn 2ϩ , and migration was measured using the inverted coverslip assay. The addition of Mn 2ϩ reversed the inhibitory effect of clustered EphrinA5 on Schwann cell migration on laminin (Fig. 6 E-G) .
In the experiments above, we showed that the inhibitory effect of astrocytes on Schwann cell migration can be overcome by blocking VAV2 signaling (Fig. 5A-F ) . Experiments from other studies have shown that Eph-mediated effects are abolished in VAV2/VAV3 knock-out animals (Cowan et al., 2005) . We therefore asked whether a deficiency of VAV2 blocks the effect of ephrinA5 on integrin-mediated migration of Schwann cells on laminin. VAV2 knockdown was achieved using the same paradigm as was used for the migration assay on astrocytes. At 48 h after application of siRNA, the Schwann cell migration assay was performed in the presence of clustered ephrinA5. VAV2 knockdown abolished the inhibitory effect of ephrinA5 on Schwann cell migration on laminin (Fig. 6 H-J ) . We further verified this result using a different independent strand of siRNA against VAV2 to ensure that the observed results were not attributable to off-target effects (supplemental Fig. 4 , available at www.jneurosci.org as supplemental material). VAV2 knockdown using this strand, in the presence of clustered ephrinA5, increased Schwann cell migration as before, supporting a role for VAV2 in inhibiting integrin-mediated migration on laminin.
Together, our results suggest that ephrinAs produced by astrocytes are involved in inhibition of Schwann cell migration and that this effect is mediated through EphA receptors on Schwann cells, leading to VAV2 signaling and interception of integrin function.
Discussion
Ephs and ephrins play important roles in cell segregation and tissue boundary formation (Mellitzer et al., 1999) and in the guidance of neural crest migration (Krull et al., 1997) . Schwann cells are neural crest derived (Jessen and Mirsky, 2005) , so we hypothesized that they might retain their ephrin-mediated guidance mechanisms. The inability of Schwann cells to mingle with astrocytes might therefore involve Eph/ephrin interactions.
We investigated the types of ephrin produced by astrocytes and the Eph receptors on Schwann cells. Both cells produce sev- eral Ephs and ephrins, with astrocytes producing ephrinA1-ephrinA5 and Schwann cells producing EphA2, EphA4, and EphA7 as potential receptors. Our findings are in agreement with other studies that have reported the presence of ephrinA1 (Sobel, 2005) , ephrinA3 (Sobel, 2005) , and ephrinA5 (Winslow et al., 1995) in astrocytes. Our Schwann cells were 96.5% pure based on S100 staining, so these results are unlikely to be influenced by fibroblast contamination. Applying the various astrocyte ephrins to Schwann cells, we saw that ephrinA1, ephrinA3, and ephrinA5 were able to inhibit Schwann cell migration on a laminin surface. There is considerable promiscuity of binding between Eph and ephrin receptors, so these ephrins could have several possible Eph receptors (Haramis and Perrakis, 2006) . EphA4 has been shown previously to play an important role after spinal cord injury. EphA4 knock-out animals show enhanced axon regeneration and less glial scarring after spinal cord injury (Goldshmit et al., 2004) , and EphA4-blocking peptides have been shown to enhance spinal axon regeneration (Fabes et al., 2007) . Based on this, we hypothesized that EphAs, such as EphA4, on Schwann cells may mediate the inhibitory effect of ephrinAs. This receptor can be blocked by EphA4 -Fc, so we tested the ability of this compound to affect Schwann cell migration on astrocyte monolayers and the intermingling of Schwann cells and astrocytes. In both assays, soluble EphA4 -Fc increased Schwann cell migration and intermingling. This result supports the hypothesis that astrocyte-produced ephrinAs inhibit Schwann cell migration via the EphA receptors. It is important to notice that EphA4 -Fc, in addition to blocking ephrinA binding to EphA4, may also disrupt the binding of ligands to other EphA receptors as a result of the promiscuity in the receptor-ligand binding. Therefore, the effect of this peptide on other EphA receptors cannot be excluded. However, application of other EphAs, including EphA2 and EphA7, did not affect Schwann cell migration or intermingling with astrocytes, supporting a more prominent role of EphA4.
In addition, because both Schwann cells and astrocytes express ephrinA5 and EphA4, we performed a comparative Western immunoblotting for these two proteins in these two cell types and demonstrated that the astrocytic surface has higher levels of ephrinA5 compared with Schwann cells, further supporting the involvement of ephrin-induced repulsion in boundary formation between astrocytes and Schwann cells.
Various signaling pathways have been suggested for downstream signaling from Eph receptors, with strong recent evidence implicating VAV proteins (Cowan et al., 2005) . VAV proteins belong to that guanidine nucleotide exchange factor family, which has been shown to modulate the activity of Rho, Rac, and Cdc42 (Hornstein et al., 2004) . They may either promote cell migration by promoting Rac1 activation (Hunter et al., 2006) or inhibit migration by activation of RhoA (Yamauchi et al., 2004) . VAV2 is the main VAV subtype present in Schwann cells, and BDNF affects Schwann cell behavior via VAV2 and RhoA (Yamauchi et al., 2004) . We therefore investigated whether VAV2 is the pathway through which ephrinA5 affects Schwann cell migration. We found that ephrinA5 application increases the phosphorylation of VAV2 in Schwann cells. Moreover, where Schwann cells are in contact with astrocytes, there is increased phosphorylation of VAV2 within them. These findings are in agreement with a previous study showing recruitment and phosphorylation of VAV GEFs after the activation of Eph receptors (Cowan et al., 2005) . Because cells from VAV2/3 knock-out animals have been shown to lose responsiveness to Eph activation (Cowan et al., 2005) , we asked whether the VAV2 is required for the astrocyte-mediated inhibition of Schwann migration. We demonstrate that VAV2 siRNA-treated cells show enhanced migration on astrocytic monolayers, suggesting that this GEF is involved in Eph/Ephrin-mediated Schwann cell-astrocyte interactions.
Schwann cell migration is dependent on integrins. In our experiments, we examined Schwann cell migration on laminin, which has been shown previously to be dependent on the ␤1 class of integrins (Milner et al., 1997) , and we also have evidence that Schwann cell migration on astrocytes is integrin dependent. We therefore hypothesized that ephrin binding to Schwann cell EphA receptor might affect integrin function. There is previous evidence suggesting that Eph activation can modulate various processes such as cell adhesion, neurite outgrowth, synapse formation, and migration by modulating integrin function (Davy and Robbins, 2000; Miao et al., 2000; Deroanne et al., 2003; Bourgin et al., 2007) .
When activated integrins engage with a ligand, they signal by increasing the phosphorylation of FAK (Schmitz et al., 2005; Robles and Gomez, 2006) , and previous studies have shown that Eph receptor activation can reduce the phosphorylation of FAK (Miao et al., 2000; Bourgin et al., 2007) . We find that this mechanism operates in Schwann cells, because we show that application of ephrinA5 reduces the phosphorylation of FAK in Schwann cells. If astrocyte-produced ephrinA5 is responsible for inhibiting Schwann cell migration by modulating integrin function, it should be possible to see a reduction in pFAK where the cell types are in contact. We saw a reduction in pFAK, but only in Schwann cells in direct contact with the astrocytes. The effects of inhibitory molecules that affect integrin activation and signaling can generally be overcome by forcing integrins into the activated state by treatment with Mn 2ϩ (Ivins et al., 2000; Miao et al., 2000) . Application of Mn 2ϩ in our experiments overcame the inhibitory effect of clustered ephrinA5 on Schwann cell migration, providing additional evidence that the action of ephrinAs on Schwann cells affects migration through the modulation of integrin function. We further show that knockdown of VAV2 abolishes the inhibitory effect of ephrinA5 on integrin-mediated Schwann cell migration on laminin.
Our results demonstrate a sequence of events whereby ephrinAs produced by astrocytes hinder Schwann cell migration by activating their EphA receptors, signaling through VAV2, and affecting integrin function. This is not the only mechanism that affects Schwann cell-astrocyte interactions. N-cadherin is responsible for homotypic and heterotypic adhesion between the cell types, and this powerful adhesion inhibits Schwann cell migration on astrocytes and cell mixing (Wilby et al., 1999; Fairless et al., 2005) . Both N-cadherin and Ephs have been shown previously to be involved in the sorting and guidance of neural crest cells from which Schwann cells are derived (Jessen and Mirsky, 2005; Kasemeier-Kulesa et al., 2006) .
There is also evidence for the involvement of astrocyteproduced CSPGs in the restriction of Schwann cell migration and intermingling (Grimpe et al., 2005) . At Schwann cell-astrocyte boundaries, the astrocytes hypertrophy and upregulate levels of neurocan and other CSPGs (Lakatos et al., 2000; Plant et al., 2001 ). FGF2 and heparan sulfate proteoglycans have been shown to be involved in this astrocytic reaction (Santos-Silva et al., 2007) , but it is probable that Eph/ephrin mechanisms may also be involved because, in EphA4 knock-out animals, there is reduced glial scar formation after injury (Goldshmit et al., 2004) .
In summary, we have demonstrated a role for Ephs and ephrins in the migration and intermingling of Schwann cells in relation to astrocytes. We show that this effect is mediated through VAV2 signaling and inhibition of integrin function.
